Skip to main content

Table 1 Demographics and baseline characteristics of the participants

From: The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial

  MPD/Placebo Placebo/MPD
(n = 20) (n = 19)
Age (y)   
Mean* 9.60 +/-2.02 8.98 +/-1.63
Range 7.09-12.99 7.21-11.81
Gender   
Male 16 (80.0%) 13 (68.4%)
Female 4 (20.0%) 6 (31.6%)
Weight (kg)* 29.34 (5.91) 29.04 (6.14)
Height (cm)* 132.50 (10.09) 133.63 (9.15)**
School backwardness 6 (30.0%) 7 (36.8%)
IQ* 102.0 (12.5) 94.6 (11.2)
Conners’ global index-Parents* 66.2 (13.9) 69.8 (16.1)
Conners’ global index-Teacher* 55.9 (8.4)¥ 59.8 (9.0) ¥
Conners’ global index-Short version-Parents* 15.2 (5.2) 13.7 (6.4)
Conners’ global index-Short version-Teacher* 8.1 (4.7)¤ 11.9 (6.1)**
CDRS-R* 29.9 (7.8) 27.6 (7.4)
CDI* 11.0 (6.5) 10.0 (4.6)
STAI-C 1* 12.9 (7.4) 10.9 (6.5)
STAI-C 2* 15.9 (9.1) 13.3 (7.5)
DSM IV THADA [28]   
Inattention* 6.8 (1.5) 6.9 (2.0)
Hyperactivity/Impulsivity* 5.3 (2.0) 5.8 (3.0)
Hyperactivity* 3.0 (1.6) 3.9 (2.1)
Impulsivity* 2.3 (0.7) 1.9 (1.2)
  1. *Mean +/- SD.
  2. According to the difference between the child age and the expected age for the school level.
  3. **3 missing values.
  4. 1 missing value.
  5. 2 missing values.
  6. ¥4 missing values.
  7. ¤5 missing values.